胰蛋白酶市场－全球产业规模、份额、趋势、机会、预测：按原料、应用、最终用户、地区和竞争对手划分，2021-2031年

全球胰蛋白酶市场预计将从 2025 年的 9,976 万美元成长到 2031 年的 1.4047 亿美元，复合年增长率为 5.87%。

胰蛋白酶是丝胺酸蛋白酶，主要萃取自牲畜的胰腺，能够将蛋白质分解成胜肽和胺基酸。在生物製药领域，它是细胞分离、疫苗研发和胰岛素生产的关键试剂；而在食品工业中，它有助于改善食品的质地和消化率。这一增长得益于该行业对生命科学的强烈依赖。根据生技创新组织（BIO）预测，到2024年，美国上市生技公司的营收预计将成长6.8%，达到2,050亿美元，显示强劲的资金筹措环境支撑了对胰蛋白酶等关键生物製程工具的需求。

儘管前景乐观，但市场在原料采购方面仍面临许多挑战。依赖动物性萃取物会对供应链带来风险，例如牲畜疾病和病毒污染，因此需要严格的法律规范。为解决这些安全问题，必须采用严格且成本高昂的纯化製程才能达到药品标准。因此，动物性原料采购的不稳定性以及难以保证产品无病原体，都构成了阻碍胰蛋白酶产品全球扩充性和商业性应用的重大瓶颈。

市场驱动因素

生物製药产业和疫苗生产的扩张，以及酵素在细胞培养通讯协定中的关键作用，是全球胰蛋白酶市场的主要驱动力。胰蛋白酶仍然是用于黏附细胞收集和组织分离的标准蛋白水解剂，而这些步骤是病毒载体和疫苗生产的关键步骤。随着大型製药公司扩大生产以对抗感染疾病，上游生物製程对高纯度胰蛋白酶的需求激增。这种成长动能体现在大规模的基础设施投资中，例如赛诺菲在2024年5月宣布投资5.86亿美元在多伦多建立先进的疫苗生产设施，这将直接推动对关键试剂的营运需求。

此外，这种酵素在商业胰岛素生产中发挥着至关重要的作用，它能将胰岛素原酶促裂解为活性胰岛素，进而推动市场发展。这项功能对于满足全球日益增长的糖尿病治疗需求至关重要。世界卫生组织（WHO）预测，到2024年，全球糖尿病成人患者人数将超过8亿，这将对供应链造成巨大压力，迫使其扩大药品生产规模。主要生产商正透过快速扩建基础设施来应对这项挑战；例如，诺和诺德公司于2024年6月宣布投资41亿美元，在美国建造第二座灌装和包装工厂。这凸显了该公司积极拓展胰蛋白酶依赖型胰岛素业务的决心。

市场挑战

对动物性萃取物的依赖是全球胰蛋白酶市场扩充性的一大障碍。由于胰蛋白酶主要来自于猪、牛等牲畜的胰腺，其供应链极易受到生物风险和农业波动的影响。这种依赖性使得生产商面临传染病爆发导致的突发性供应中断，进而引发原材料数量限制以及对来自疫区的动物产品实施严格的监管禁运。

这些生物威胁导致市场不稳定。根据世界动物卫生组织（OIE）称，2024年持续蔓延的非洲猪瘟已影响60多个国家的家猪，严重限制了用于胰蛋白酶提取的猪源性原料的贸易和供应。如此广泛的疾病爆发迫使生产者实施复杂的安全措施，以确保原料不含病原体。因此，需要进行严格的病毒灭活和纯化，从而增加了生产成本和前置作业时间。这成为限制生物製药产业高效满足日益增长的需求的主要瓶颈。

市场趋势

将胰蛋白酶整合到自动化高通量蛋白质体学工作流程中，正在从根本上改变市场模式。研究机构需要能够在大规模样品製备中提供卓越一致性的酵素解决方案。高活性和高稳定性的胰蛋白酶对于现代分析平台至关重要，能够确保更快、可重复且完全的蛋白质消化，这对于大规模人群健康研究至关重要。这种向大规模、高效处理的转变正在推动对专用级试剂的采用，以支援连续运行。正如赛默飞世尔科技公司在2025年1月的新闻稿中所述，英国生物银行药物蛋白质体学计划采用了他们的平台，分析了来自约60万个检体的5,400多种蛋白质。这一规模凸显了高通量生物学研究对酵素试剂日益增长的需求。

此外，胰蛋白酶（一种胰臟酶）在培养肉和细胞农业领域的应用日益广泛，预示着新的消费领域的涌现。这种酵素对于生物质收穫和维持细胞增殖过程中的细胞活力至关重要。随着这一新兴领域从试点研究走向商业化生产，大量投资正被用于优化生物製程并确保关键原料的供应链。这种对规模化生产的重视对于细胞衍生蛋白产品的商业性至关重要。根据良好食品研究所（Good Food Institute）2025年3月发布的报告，该领域展现出强劲的韧性，Prolific Machines公司已完成5,460万美元的B轮资金筹措。这笔投资将用于推进依赖这些关键细胞培养组件的生物製造技术。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球胰蛋白酶市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依原料分类（猪肉来源、牛来源、其他）
  • 按应用领域（生物技术/製药业、食品业、化妆品/个人护理、废弃物处理、其他）
  • 按最终用户（调查、诊断、工业应用）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美胰蛋白酶市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲胰蛋白酶市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区胰蛋白酶市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东与非洲胰蛋白酶市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲胰蛋白酶市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球胰蛋白酶市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Merck KGaA
• Novozymes A/S, part of Novonesis Group
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc
• Sartorius AG
• Bioseutica BV
• Biozym Scientific GmbH
• PromoCell GmbH
• Promega Corporation
• Bovogen Biologicals Pty Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Trypsin Market is projected to expand from USD 99.76 Million in 2025 to USD 140.47 Million by 2031, reflecting a CAGR of 5.87%. As a serine protease primarily extracted from the pancreas of livestock, trypsin functions by breaking down proteins into peptides and amino acids. It acts as a pivotal reagent within the biopharmaceutical sector for cell dissociation, vaccine development, and insulin manufacturing, while also enhancing texture and digestibility in the food industry. The sector's heavy dependence on life sciences fuels this growth; according to the Biotechnology Innovation Organization, revenue for U.S. public bioscience companies increased by 6.8% to $205 billion in 2024, indicating a strong funding landscape that sustains the demand for critical bioprocessing tools like trypsin.

Despite this positive outlook, the market encounters substantial obstacles regarding raw material procurement. The reliance on animal-derived extraction subjects the supply chain to risks involving livestock diseases and viral contamination, necessitating strict regulatory oversight. These safety issues require rigorous, expensive purification procedures to satisfy pharmaceutical standards. Consequently, the instability of animal sourcing and the difficulty of guaranteeing pathogen-free products generate significant bottlenecks that hinder the global scalability and commercial reach of trypsin products.

Market Driver

The expansion of the biopharmaceutical sector and vaccine production serves as a major catalyst for the Global Trypsin Market, fueled by the enzyme's essential role in cell culture protocols. Trypsin remains the standard proteolytic agent for harvesting adherent cells and tissue dissociation, a critical step in manufacturing viral vectors and vaccines. As pharmaceutical leaders ramp up production to address infectious diseases, the demand for high-grade trypsin for upstream bioprocessing has escalated. This momentum is highlighted by significant infrastructure investments, such as Sanofi's May 2024 announcement of a $586 million investment to open an advanced vaccine manufacturing facility in Toronto, which directly drives operational demand for key reagents.

Furthermore, the market is driven by the enzyme's critical role in commercial insulin manufacturing, where it is used to enzymatically cleave proinsulin into active insulin. This function is essential for addressing the growing global need for diabetes treatments. According to the World Health Organization, the number of adults with diabetes worldwide exceeded 800 million in 2024, placing immense pressure on supply chains to boost therapeutic production. Major manufacturers are responding with rapid infrastructure expansion; for example, Novo Nordisk announced a $4.1 billion investment in June 2024 to construct a second fill and finishing facility in the US, underscoring the aggressive scaling of insulin operations dependent on trypsin.

Market Challenge

The dependence on animal-derived extraction poses a significant barrier to the scalability of the Global Trypsin Market. Because trypsin is primarily sourced from the pancreas of livestock, such as pigs and cattle, the supply chain is intrinsically susceptible to biological risks and agricultural volatility. This reliance exposes manufacturers to abrupt disruptions from epizootic outbreaks, which limit raw material volumes and trigger strict regulatory embargoes on animal by-products from impacted areas.

These biological threats result in market instability. According to the World Organisation for Animal Health, the continued spread of African Swine Fever in 2024 impacted domestic swine populations in more than 60 countries, severely limiting the trade and availability of porcine materials needed for trypsin extraction. Such widespread disease prevalence compels manufacturers to implement complex safety measures to ensure pathogen-free ingredients. The consequent need for rigorous viral inactivation and purification increases production costs and lead times, creating a major bottleneck that hampers the industry's capacity to efficiently satisfy the biopharmaceutical sector's growing demand.

Market Trends

The integration of trypsin into automated high-throughput proteomics workflows is fundamentally altering the market, as research institutions require enzyme solutions capable of delivering exceptional consistency for large-scale sample preparation. Modern analytical platforms demand highly active and stable trypsin to ensure reproducible and complete protein digestion within shorter timeframes, a necessity for population-scale health research. This shift toward massive, streamlined processing drives the uptake of specialized reagent grades that support continuous operation. As noted in a January 2025 press release from Thermo Fisher Scientific, the UK Biobank Pharma Proteomics Project selected the company's platform to analyze over 5,400 proteins across roughly 600,000 samples, a scale that highlights the rising volume of enzymatic reagents required for high-throughput biological studies.

Additionally, the rising application of trypsin in cultivated meat and cellular agriculture marks a growing frontier for consumption, where the enzyme is essential for harvesting biomass and maintaining cell viability during expansion. As this emerging sector moves from pilot research to commercial manufacturing, significant investment is being focused on optimizing bioprocesses and securing supply chains for key inputs. This emphasis on scaling is crucial for making cell-based protein products commercially accessible. According to The Good Food Institute's March 2025 report, the sector showed resilience with Prolific Machines securing a $54.6 million Series B funding round, an investment dedicated to advancing biomanufacturing technologies that depend on these critical cell culture components.

Key Market Players

• Merck KGaA
• Novozymes A/S, part of Novonesis Group
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc
• Sartorius AG
• Bioseutica BV
• Biozym Scientific GmbH
• PromoCell GmbH
• Promega Corporation
• Bovogen Biologicals Pty Ltd

Report Scope

In this report, the Global Trypsin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Trypsin Market, By Source

• Porcine
• Bovine
• Others

Trypsin Market, By Application

• Biotechnology and Pharmaceutical Industry
• Food Industry
• Cosmetics and Personal Care
• Waste Treatment
• Others

Trypsin Market, By End User

• Research
• Diagnostics
• Industrial use

Trypsin Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Trypsin Market.

Available Customizations:

Global Trypsin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Trypsin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Source (Porcine, Bovine, Others)
  • 5.2.2. By Application (Biotechnology and Pharmaceutical Industry, Food Industry, Cosmetics and Personal Care, Waste Treatment, Others)
  • 5.2.3. By End User (Research, Diagnostics, Industrial use)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Trypsin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Source
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Trypsin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Source
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Trypsin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Source
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Trypsin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Source
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Trypsin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Source
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Trypsin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Source
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Trypsin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Source
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Trypsin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Source
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Trypsin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Source
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Trypsin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Source
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Trypsin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Source
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Trypsin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Source
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Trypsin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Source
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Trypsin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Source
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Trypsin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Source
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Trypsin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Source
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Trypsin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Source
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Trypsin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Source
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Trypsin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Source
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Trypsin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Source
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Trypsin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Source
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Trypsin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Source
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Trypsin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Source
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Trypsin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Source
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Trypsin Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novozymes A/S, part of Novonesis Group
• 15.3. Agilent Technologies, Inc.
• 15.4. Thermo Fisher Scientific Inc
• 15.5. Sartorius AG
• 15.6. Bioseutica BV
• 15.7. Biozym Scientific GmbH
• 15.8. PromoCell GmbH
• 15.9. Promega Corporation
• 15.10. Bovogen Biologicals Pty Ltd

16. Strategic Recommendations

17. About Us & Disclaimer